IP Library Granted Patent US 9,920,066
Granted Patent B2
US 9,920,066 · App. 15/436,988 · Granted Mar 20, 2018

Thienopyrimidine compounds

Inventors: Allan Jordan (Winnersh, GB); Simon Bedford (Winnersh, GB); Klenke Burkhard (Winnersh, GB); Ian Yule (Winnersh, GB); Karine Poullennec (Winnersh, GB)
Assignee: Vernalis (R&D) Ltd.
C07D495/04A61K31/519C07D495/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,920,066
App. No.
15/436,988
Granted
Mar 20, 2018
Kind
B2
Abstract

Compounds of formula (I) are A 2B receptor antagonists: Wherein R 1 is optionally substituted aryl or an optionally substituted 5- or 6-membered heteroaryl ring; R 2 and R 3 are independently selected from hydrogen, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkyl-(C 1 -C 6 )-alkyl, aryl-(C 1 -C 6 )-alkyl optionally substituted in the ring part thereof, a 5- or 6-membered monocyclic heterocyclic group optionally linked via a C 1 -C 6 alkylene chain and optionally substituted in the ring part thereof, benzimidazol-2-yl-methyl, pyrid-3-yl-carbonyl, or (1-methyl-piperidin-4-yl)-carbonyl-methyl; or R 2 and R 3 taken together with the nitrogen atom to which they are attached form an optionally substituted 5- or 6-membered ring; R 4 is C 1 -C 3 alkyl, C 2 -C 3 alkenyl, —N(—R 5 )—R 6 , or optionally substituted heteroarylmethylamino; and R 5 and R 6 are independently selected from hydrogen or C 1 -C 3 alkyl; or R 5 and R 6 taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 6-membered saturated ring.

Claims (13)

1. A compound having the formula:

wherein

R 1 is a furan, thiophene, pyrrole, oxazole, thiazole, imidazole, or pyridine; optionally substituted with fluoro, chloro, bromo, cyano, methyl, trifluoromethyl, ethyl, hydroxyl, hydroxymethyl, or hydroxyethyl;

R 2 is hydrogen;

R 3 is a 5- or 6-membered monocyclic heterocyclic group optionally linked via a C 1 -C 6 alkylene chain and optionally substituted in the ring part thereof by fluoro, chloro, bromo, cyano, methyl, trifluoromethyl, ethyl, hydroxyl, hydroxymethyl, or hydroxyethyl;

R 4 is C 1 -C 3 alkyl.

2. The compound of claim 1 wherein R 1 is an unsubstituted furan, thiophene, pyrrole, oxazole, thiazole, imidazole, or pyridine.

3. The compound of claim 1 wherein R 1 is a furan, thiophene, pyrrole, oxazole, thiazole, imidazole, or pyridine; substituted with fluoro, chloro, bromo, cyano, methyl, trifluoromethyl, ethyl, hydroxyl, hydroxymethyl, or hydroxyethyl.

4. The compound of claim 1 wherein R 3 is a pyran piperidine, morpholine, imidazole, pyridine, pyrimidine, pyrazine, or tetrazole linked via a C 1 -C 6 alkylene chain and optionally substituted in the ring part thereof by fluoro, chloro, bromo, cyano, methyl, trifluoromethyl, ethyl, hydroxyl, hydroxymethyl, or hydroxyethyl.

5. The compound of claim 1 wherein R 3 is a pyridine linked via a C 1 -C 6 alkylene chain and optionally substituted in the ring part thereof by fluoro, chloro, bromo, cyano, methyl, trifluoromethyl, ethyl, hydroxyl, hydroxymethyl, or hydroxyethyl.

6. The compound of claim 1 wherein R 3 is a pyridine linked via an ethylene and optionally substituted in the ring part thereof by fluoro, chloro, bromo, cyano, methyl, trifluoromethyl, ethyl, hydroxyl, hydroxymethyl, or hydroxyethyl.

7. The compound of claim 1 wherein R 3 is a pyridine linked via an ethylene and substituted in the ring part thereof by fluoro, chloro, bromo, cyano, methyl, trifluoromethyl, ethyl, hydroxyl, hydroxymethyl, or hydroxyethyl.

8. A method of treating cancer, said method comprising administering to a subject in need thereof an effective amount of a compound of claim 1 .

Assignments (3)
CHANGE OF NAME Recorded Jan 24, 2022
From: VERNALIS DEVELOPMENT LIMITED
To: LIGAND UK DEVELOPMENT LIMITED
Reel/Frame 058738/0271 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2022
From: VERNALIS (R&D) LIMITED
To: VERNALIS DEVELOPMENT LIMITED
Reel/Frame 058822/0570 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 1, 2017
From: JORDAN, ALLAN; BEDFORD, SIMON; BURKHARD, KLENKE; YULE, IAN; POULLENNEC, KARINE
To: VERNALIS (R&D) LTD.
Reel/Frame 043150/0500 →
Priority Claims (1)
GB 0718434.4 · Sep 21, 2007 · national
Continuity (3)
Continuation 14803214 · Jul 20, 2015
Continuation 12678378
Related Publication 20170291907A1 · Oct 12, 2017